Comparative Effectiveness of Basal-Bolus Versus Premix Analog Insulin on Glycemic Variability and Patient-Centered Outcomes during Insulin Intensification in Type 1 and Type 2 Diabetes: A Randomized, Controlled, Crossover Trial
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
CONTEXT: In patients with diabetes, intraday glucose variability might predict health outcomes independently from glycosylated hemoglobin (HbA1c). OBJECTIVE: Our objective was to evaluate patient satisfaction (PS), quality of life (QoL), glycemic control, and variability during insulin intensification to HbA1c below 7.0%. PATIENTS, DESIGN, AND SETTING: Eighty-two type 1 and 306 insulin-treated type 2 diabetes patients (47% male; age 54±11 yr; HbA1c=7.8±0.7%) participated in this multicenter, randomized, crossover trial at 52 U.S. centers. INTERVENTIONS: Interventions included insulin glargine plus premeal glulisine (n=192) vs. twice-daily premix 75/25 or 70/30 analog insulin (n=196) for 12 wk and crossed to the alternate arm for 12 wk. MAIN OUTCOME MEASURES: Main outcome measures included PS and QoL questionnaires, 3-d continuous glucose monitoring (CGM), and HbA1c every 4-8 wk. RESULTS: Mean±se HbA1c change was -0.39±0.09% for glargine-glulisine and -0.05±0.09% for premix (P<0.0001). The PS net benefit scale (0-100) improved from 51.1 to 60.5±1.2 for glargine-glulisine and worsened to 45.4±1.2 for premix (P<0.0001). The PS regimen acceptance scale was comparable (P=0.33). Overall QoL favored glargine-glulisine (P<0.001), as did perceived health (P<0.0001), symptom distress (P<0.0001), general health perceptions (P<0.01), and psychosocial (P<0.02). CGM daily glucose mean, daily glucose sd (glycemic variability), and percent time over 140 mg/dl were lower for glargine-glulisine by 13.1±2.7 mg/dl, 5.9±1.4 mg/dl, and 7.3±1.6%, respectively (all P<0.0001), with no difference in CGM percent time below 70 mg/dl (P=0.09). Symptomatic hypoglycemia rates were comparable. HbA1c, mean CGM daily glucose, and glycemic variability were independent predictors of PS net benefit. CONCLUSIONS: Patient satisfaction was impacted more positively by improved QoL, reduced glucose variability, and better glycemic control with a basal-bolus regimen than negatively by the burden of additional injections, thereby facilitating insulin intensification and the ability to achieve HbA1c below 7.0%.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Standards of medical care in diabetes 2010
American Diabetes Association (2010) · Diabetes Care · doi:10.2337/dc10-s011 · Cited by 3,470
U.K. Prospective Diabetes Study Group (1995) · Diabetes · doi:10.2337/diab.44.11.1249 · Cited by 1,923
Riddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479
Injection related anxiety in insulin-treated diabetes
Zambanini, A., Newson, R. B., Maisey, M., & Feher, M. D. (1999) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(99)00099-6 · Cited by 289
Herman, W. H., Ilag, L. L., Johnson, S. L., Martin, C. L., Sinding, J., Al Harthi, A., Plunkett, C. D., LaPorte, F. B., Burke, R., Brown, M. B., et al. (2005) · Diabetes Care · doi:10.2337/diacare.28.7.1568 · Cited by 265
Blonde, L., Merilainen, M., Karwe, V., Raskin, P., & TITRATE™ Study Group (2009) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01060.x · Cited by 180
Self-citationLow fasting plasma glucose level as a predictor of cardiovascular disease and all-cause mortality
Wei, M., Gibbons, L. W., Mitchell, T. L., Kampert, J. B., Stern, M. P., & Blair, S. N. (2000) · Circulation · doi:10.1161/01.cir.101.17.2047 · Cited by 142
Association of glucose levels and glucose variability with mood in type 1 diabetic patients
Hermanns, N., Scheff, C., Kulzer, B., Weyers, P., Pauli, P., Kubiak, T., & Haak, T. (2007) · Diabetologia · doi:10.1007/s00125-007-0643-y · Cited by 66 · cited 1×
“One small sample of 36 patients studied at one point in time found that although levels of high glucose were associated with poorer mood ratings, glycemic variability was not found to be an independent predictor (17).”
BackgroundTesta, M. A., Turner, R. R., Simonson, D. C., Krafcik, M. B., Calvo, C., & Luque-Otero, M. (1998) · Journal of Hypertension · doi:10.1097/00004872-199816120-00018 · Cited by 40
Self-citation
Cited by
DeFronzo, R. A., Ferrannini, E., Groop, L., Henry, R. R., Herman, W. H., Holst, J. J., Hu, F. B., Kahn, C. R., Raz, I., Shulman, G. I., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.19 · Cited by 2,611
Self-citationBergenstal, R. M., Ahmann, A. J., Bailey, T., Beck, R. W., Bissen, J., Buckingham, B., Deeb, L., Dolin, R. H., Garg, S. K., Goland, R., et al. (2013) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2013.0051 · Cited by 307
Bergenstal, R. M. (2015) · Diabetes Care · doi:10.2337/dc15-0099 · Cited by 140
Minimizing Glycemic Fluctuations in Patients with Type 2 Diabetes: Approaches and Importance
Dandona, P. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0372 · Cited by 67
Manski‐Nankervis, J., Yates, C. J., Blackberry, I., Furler, J., Ginnivan, L., Cohen, N., Jenkins, A., Vasanthakumar, S., Gorelik, A., Young, D., et al. (2016) · Diabetic Medicine · doi:10.1111/dme.12979 · Cited by 8
Metadata
- Authors
- Testa, M. A., Gill, J., Su, M., Turner, R. R., Blonde, L., & Simonson, D. C.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2012-10
- Volume
- 97
- Issue
- 10
- Pages
- 3504-3514
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2142479519
- Cited by
- 50
- References
- 9
- FWCI
- 4.37
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comparative Effectiveness of Basal-Bolus Versus Premix Analog Insulin on Glycemic Variability and Patient-Centered Outcomes during Insulin Intensification in Type 1 and Type 2 Diabetes: A Randomized, Controlled, Crossover Trial. https://app.cochat.ai/papers/10.1210/jc.2012-1763
- The paper
- Testa, M. A., Gill, J., Su, M., Turner, R. R., Blonde, L., & Simonson, D. C. (2012). Comparative Effectiveness of Basal-Bolus Versus Premix Analog Insulin on Glycemic Variability and Patient-Centered Outcomes during Insulin Intensification in Type 1 and Type 2 Diabetes: A Randomized, Controlled, Crossover Trial. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2012-1763
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.